Literature DB >> 15668521

Pharmacogenomics and systems biology of membrane transporters.

Qing Yan1.   

Abstract

Membrane transporters are essential for fundamental cellular functions and normal physiological processes. These molecules influence drug absorption and distribution, and play key roles in drug therapeutic effects. A primary goal of current research in drug discovery and development is to fully understand the interaction between transporters and drugs at both system level and individual level for personalized therapy. Pharmacogenomics studies the genetic basis of the individual variations in response to drug therapy, whereas systems biology provides the understanding of biological processes at the system level. The integration of pharmacogenomics with systems biology in membrane transporter study is necessary to solve complex problems in diseases and drug effects. Such integration provides insight to key issues of pharmacogenomics and systems biology of membrane transporters. These key issues include the correlations between structure and function, genotype and phenotype, and systematic interactions between different transporters, between transporters and other proteins, and between transporters and drugs. The exploration in these key issues may ultimately contribute to the personalized medicine with high efficacy but less toxicity, which is the overall goal of pharmacogenomics and systems biology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668521     DOI: 10.1385/MB:29:1:75

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  79 in total

Review 1.  Drug transport and targeting. Intestinal transport.

Authors:  D M Oh; H K Han; G L Amidon
Journal:  Pharm Biotechnol       Date:  1999

2.  Impact of pharmacogenomics on the clinical laboratory.

Authors:  P Hess; D Cooper
Journal:  Mol Diagn       Date:  1999-12

Review 3.  Novel animal-health drug targets from ligand-gated chloride channels.

Authors:  Valérie Raymond; David B Sattelle
Journal:  Nat Rev Drug Discov       Date:  2002-06       Impact factor: 84.694

Review 4.  Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?

Authors:  D W Nebert
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

Review 5.  Impact of genomics on drug discovery and clinical medicine.

Authors:  G Emilien; M Ponchon; C Caldas; O Isacson; J M Maloteaux
Journal:  QJM       Date:  2000-07

6.  A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease.

Authors:  D Rund; I Azar; O Shperling
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

Review 7.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

Authors:  J König; A T Nies; Y Cui; I Leier; D Keppler
Journal:  Biochim Biophys Acta       Date:  1999-12-06

8.  Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel.

Authors:  H A Berger; M P Anderson; R J Gregory; S Thompson; P W Howard; R A Maurer; R Mulligan; A E Smith; M J Welsh
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

9.  Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking.

Authors:  P H Dixon; N Weerasekera; K J Linton; O Donaldson; J Chambers; E Egginton; J Weaver; C Nelson-Piercy; M de Swiet; G Warnes; E Elias; C F Higgins; D G Johnston; M I McCarthy; C Williamson
Journal:  Hum Mol Genet       Date:  2000-05-01       Impact factor: 6.150

Review 10.  Unified inventory of established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae.

Authors:  I T Paulsen; M K Sliwinski; B Nelissen; A Goffeau; M H Saier
Journal:  FEBS Lett       Date:  1998-06-23       Impact factor: 4.124

View more
  1 in total

1.  Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition.

Authors:  S Ekins; J E Polli; P W Swaan; S H Wright
Journal:  Clin Pharmacol Ther       Date:  2012-09-26       Impact factor: 6.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.